AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26542691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic computed tomographic angiography (CTA)
Number of subjects: 70
Study 26542691 — intervention group
Group type: COMPARATOR
Intervention: Single-phase CTA
Number of subjects: 70
Study 26542691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CTA
Number of subjects: 70
Study 26543510 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg daily oral pioglitazone for 28 days
Number of subjects: 100
Study 26543510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26543765 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A: 3-weekly epirubicin (90 mg/m2) and docetaxel (75 mg/m2) chemotherapy
Number of subjects: 93
Study 26543765 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B: 2-weekly epirubicin (60 mg/m2) and docetaxel (60 mg/m2) chemotherapy
Number of subjects: 93
Study 26543906 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone (iPhone 4S)
Number of subjects: 400
Study 26543906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawson SMART Record (LSR)
Number of subjects: 400
Study 26544192 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 40
Study 26544668 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy youth
Number of subjects: 111
Study 26544668 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious youth
Number of subjects: 111
Study 26544668 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy adults
Number of subjects: 111
Study 26544668 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious adults
Number of subjects: 111
Study 26544668 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional tasks
Number of subjects: 111
Study 26544668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonemotional tasks
Number of subjects: 111
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (161 participants)
Number of subjects: 242
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (67 participants)
Number of subjects: 242
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cohort (242 participants)
Number of subjects: 242
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with type 2 diabetes at baseline
Number of subjects: 242
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with abnormal kidney function at baseline
Number of subjects: 242
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with prediabetes at baseline
Number of subjects: 242
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with elevated blood pressure at baseline
Number of subjects: 242
Study 26544725 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with dyslipidemia at baseline
Number of subjects: 242
Study 26545441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 200 mg 1-h i.v. infusion post-haemodialysis
Number of subjects: 8
Study 26545441 — intervention group
Group type: COMPARATOR
Intervention: Ceftaroline fosamil 600 mg 1-h i.v. infusion in healthy volunteers
Number of subjects: 8
Study 26545441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 200 mg 1-h i.v. infusion pre-haemodialysis
Number of subjects: 8
Study 26545441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 200 mg 1-h i.v. infusion (pre- and post-haemodialysis)
Number of subjects: 8
Study 26545441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (pre- and post-haemodialysis)
Number of subjects: 8
Study 26545911 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombophilic SNPs (factor V Leiden, H1299R, prothrombin G20210A, factor XIII V34L, β-fibrinogen -455G → A, plasminogen activator inhibitor-1 4G/5G, human platelet antigen-1 a/b9L33P, methylenetetrahydrofolate reductase C677T and A1298C)
Number of subjects: 1717
Study 26545911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative number of thrombophilic mutations
Number of subjects: 1717
Study 26546060 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels
Number of subjects: 350
Study 26546060 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, albumin, presence of arteriovenous fistula calcification
Number of subjects: 350
Study 26546060 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 350
Study 26546259 — intervention group
Group type: EXPERIMENTAL
Intervention: 20μg dose of RVEc™
Number of subjects: 30
Study 26546259 — intervention group
Group type: EXPERIMENTAL
Intervention: 50μg dose of RVEc™
Number of subjects: 30
Study 26546259 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg dose of RVEc™
Number of subjects: 30
Study 26546259 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of RVEc™ (20-21 months after initial dose)
Number of subjects: 30
Study 26547188 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical IMRT of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated boost to the prostate (76.5 Gy) in 34 fractions, following at least two months of antihormonal treatment before radiotherapy continuing for at least 2 years.
Number of subjects: 40
Study 26547226 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink consumption
Number of subjects: 0
Study 26547226 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or no energy drink)
Number of subjects: 0
Study 26547914 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches (5-20 μg/h and 35-70 μg/h)
Number of subjects: 465
Study 26547914 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches
Number of subjects: 465
Study 26551877 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter pacemaker
Number of subjects: 725
Study 26552042 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB treatment
Number of subjects: 113
Study 26552042 — intervention group
Group type: COMPARATOR
Intervention: WEB treatment with antiplatelet agents
Number of subjects: 113
Study 26552419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MSI typing, MLH1 methylation analysis, and immunohistochemistry (IHC)
Number of subjects: 1002
Study 26552564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-based seizure detection algorithm (CBSDA) triggering Vagus Nerve Stimulation (VNS)
Number of subjects: 31
Study 26552564 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Number of subjects: 31
Study 26553234 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26553695 — intervention group
Group type: EXPERIMENTAL
Intervention: RUNX2 gene expression in calcified valves
Number of subjects: 474
Study 26553695 — intervention group
Group type: EXPERIMENTAL
Intervention: CACNA1C gene expression in calcified valves
Number of subjects: 474
Study 26553695 — intervention group
Group type: COMPARATOR
Intervention: Genome-wide association studies (GWAS) results
Number of subjects: 474
Study 26553695 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of RUNX2 with AS
Number of subjects: 474
Study 26553695 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CACNA1C with AS
Number of subjects: 474
Study 26553837 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment procedures and acceptability of participation
Number of subjects: 0
Study 26553837 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline biophysical, genetic, socioeconomic, behavioural and psychological assessments
Number of subjects: 0
Study 26553837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy and postpregnancy assessments
Number of subjects: 0
Study 26554383 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay on induced sputum samples
Number of subjects: 1020
Study 26554383 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay on gastric lavage samples
Number of subjects: 1020
Study 26554383 — intervention group
Group type: COMPARATOR
Intervention: MGIT culture on induced sputum samples
Number of subjects: 1020
Study 26554383 — intervention group
Group type: COMPARATOR
Intervention: MGIT culture on gastric lavage samples
Number of subjects: 1020
Study 26554383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results from Xpert MTB/RIF assay or MGIT culture
Number of subjects: 1020
Study 26554629 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 1915
Study 26554629 — intervention group
Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 1915
Study 26554629 — intervention group
Group type: COMPARATOR
Intervention: Nonwhite race
Number of subjects: 1915
Study 26554651 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate and gemcitabine (1.0 mg/m² eribulin and 1000 mg/m² gemcitabine on days 1 and 8 of a 28-day cycle)
Number of subjects: 45
Study 26554876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab treatment
Number of subjects: 249
Study 26554876 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of tanezumab
Number of subjects: 249
Study 26554876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab administered with nonsteroidal antiinflammatory drugs
Number of subjects: 249
Study 26554876 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting subchondral insufficiency fractures
Number of subjects: 249
Study 26555635 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 194
Study 26555635 — intervention group
Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 194
Study 26555635 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing non-fasting glucose levels
Number of subjects: 194
Study 26555692 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of undiagnosed neurological conditions in male LUTS patients
Number of subjects: 0
Study 26555692 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging (MRI scan)
Number of subjects: 0
Study 26555948 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 167
Study 26555948 — intervention group
Group type: COMPARATOR
Intervention: Risk factor assessment
Number of subjects: 167
Study 26555948 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 167
Study 26555948 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 167
Study 26556476 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (nCR)
Number of subjects: 642
Study 26556476 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant chemoradiation (no nCR)
Number of subjects: 642
Study 26556899 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-intubation within 72 hours after extubation
Number of subjects: 764
Study 26556899 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen level >8.2 mmol/L
Number of subjects: 764
Study 26556899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level <75 g/L
Number of subjects: 764
Study 26556899 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength ≤3
Number of subjects: 764
Study 26556899 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of all 3 risk factors (blood urea nitrogen >8.2 mmol/L, hemoglobin <75 g/L, muscle strength ≤3)
Number of subjects: 764
Study 26557215 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily regimen of cleanser (7.8% 1-lactic acid, 2% salicylic acid) and anti-aging serum (0.1% alpha hydroxy acids-retinoids, 6.5% 1-lactic acid) with concurrent use of sun protection factor 50+ sunscreen as needed
Number of subjects: 25
Study 26557787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control therapy
Number of subjects: 0
Study 26557787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy
Number of subjects: 0
Study 26557787 — intervention group
Group type: COMPARATOR
Intervention: Random assignment to treatments
Number of subjects: 0
Study 26557787 — intervention group
Group type: COMPARATOR
Intervention: Preference allocation to chosen treatment
Number of subjects: 0
Study 26558819 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 325
Study 26558819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 325
Study 26558829 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based violence prevention intervention
Number of subjects: 3700
Study 26558829 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of sensitisation and consent procedures
Number of subjects: 3700
Study 26558829 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral algorithm developed in conjunction with local services
Number of subjects: 3700
Study 26558829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory reporting of children's disclosures to local services
Number of subjects: 3700
Study 26559139 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β-1a 44 μg subcutaneously three times a week (SC tiw)
Number of subjects: 23
Study 26559386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valves
Number of subjects: 4545
Study 26559386 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic valves
Number of subjects: 4545
Study 26559401 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage-aged red blood cell transfusions
Number of subjects: 0
Study 26559535 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell-based tissue-engineered tracheas
Number of subjects: 3
Study 26559634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical inversion technique
Number of subjects: 40
Study 26559790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with escitalopram (mean daily dose 18.62 mg, SD 5.15) and memantine (mean daily dose 13.62 mg, SD 6.67)
Number of subjects: 35
Study 26559790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with escitalopram and memantine
Number of subjects: 35
Study 26559790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with escitalopram and memantine in the amnestic mild cognitive impairment subsample (n = 22)
Number of subjects: 35
Study 26560486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed (500 mg/m2 iv on Day 1, nintedanib 100 mg bid escalating to 200 mg bid on days 2-21)
Number of subjects: 18
Study 26560486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed
Number of subjects: 18
Study 26561620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest physical activity group (15.7 ± 9.9 min MVPA/d, 6062 ± 1778 steps/d)
Number of subjects: 421
Study 26561620 — intervention group
Group type: COMPARATOR
Intervention: Middle activity group
Number of subjects: 421
Study 26561620 — intervention group
Group type: EXPERIMENTAL
Intervention: Most-active group (174.5 ± 60.5 min MVPA/d, 10260 ± 3087 steps/d)
Number of subjects: 421
Study 26561620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest physical activity group
Number of subjects: 421
Study 26561627 — intervention group
Group type: EXPERIMENTAL
Intervention: High manganese exposure (parenteral nutrition)
Number of subjects: 73
Study 26561627 — intervention group
Group type: COMPARATOR
Intervention: Low manganese exposure (parenteral nutrition)
Number of subjects: 73
Study 26561629 — intervention group
Group type: EXPERIMENTAL
Intervention: ¹³C-lycopene (10.2 mg)
Number of subjects: 8
Study 26561916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as initial hemostasis in group A (5 mL)
Number of subjects: 37
Study 26561916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as rescue therapy in group B (5 mL)
Number of subjects: 37
Study 26562321 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals
Number of subjects: 155
Study 26562321 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients with A/H3N2 infection
Number of subjects: 155
Study 26562321 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated participants with A/H1N1 infection
Number of subjects: 155
Study 26562532 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (vancomycin 500 mg, gentamycin 40 mg, meropenem 500 mg once-daily for 4 days)
Number of subjects: 12
Study 26562532 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (vancomycin, gentamycin, meropenem)
Number of subjects: 12
Study 26562836 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ACTH (intramuscular injections, max 1 mg twice a week for 9 months)
Number of subjects: 20
Study 26562836 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and steroids (historical control)
Number of subjects: 20
Study 26563220 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated HIV counseling and family planning services
Number of subjects: 0
Study 26563220 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone services (comparison group)
Number of subjects: 0
Study 26563229 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for generalized anxiety disorder, panic disorder, social anxiety disorder (SAD), or post-traumatic stress disorder
Number of subjects: 0
Study 26563229 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for social anxiety disorder (SAD)
Number of subjects: 0
Study 26563229 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid depression and low socioeconomic status
Number of subjects: 0
Study 26563323 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024% instilled once daily (QD) for 14 days
Number of subjects: 24
Study 26563323 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024% instilled QD for 14 days
Number of subjects: 24
Study 26563363 — intervention group
Group type: EXPERIMENTAL
Intervention: BAK-free travoprost 0.004 % (Travatan® preserved with POLYQUAD®) for 12 weeks
Number of subjects: 191
Study 26564730 — intervention group
Group type: EXPERIMENTAL
Intervention: Midfoot Fusion Bolt (MFB, Synthes GmbH)
Number of subjects: 47
Study 26565008 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660 (microbiota suspension) administered via enema
Number of subjects: 40
Study 26565381 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib (RXDX-101)
Number of subjects: 1
Study 26565813 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 26565813 — intervention group
Group type: COMPARATOR
Intervention: Metabolic products of the mevalonate pathway (mevalonate, farnesyl pyrophosphate, geranylgeranyl pyrophosphate)
Number of subjects: 0
Study 26565981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 22
Study 26566161 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg twice daily with a background regimen (boosted protease inhibitor plus nucleoside/nucleotide reverse transcriptase inhibitors, optional enfuvirtide/raltegravir)
Number of subjects: 101
Study 26566161 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg twice daily
Number of subjects: 101
Study 26566324 — intervention group
Group type: EXPERIMENTAL
Intervention: Large head (Magnum) prostheses
Number of subjects: 164
Study 26566324 — intervention group
Group type: COMPARATOR
Intervention: Conventional femoral head prostheses
Number of subjects: 164
Study 26566446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bollywood dance classes (1 hour, twice per week for 8 weeks)
Number of subjects: 0
Study 26566446 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26566446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bollywood dance classes (for participants attending at least 10 of 16 sessions)
Number of subjects: 0
Study 26566446 — intervention group
Group type: COMPARATOR
Intervention: Usual care (for participants attending fewer sessions)
Number of subjects: 0
Study 26566655 — intervention group
Group type: EXPERIMENTAL
Intervention: EpCAM-based flow cytometry
Number of subjects: 29
Study 26566655 — intervention group
Group type: COMPARATOR
Intervention: CSF cytology
Number of subjects: 29
Study 26566655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell count or biochemical parameters in CSF
Number of subjects: 29
Study 26566914 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for the m.3243A>G MELAS mutation
Number of subjects: 238
Study 26566914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and cerebral MRI features review
Number of subjects: 238
Study 26566980 — intervention group
Group type: EXPERIMENTAL
Intervention: Families SHARE workbook
Number of subjects: 100
Study 26567113 — intervention group
Group type: EXPERIMENTAL
Intervention: [(64)Cu]DOTA-patritumab (9.0 mg/kg)
Number of subjects: 8
Study 26567113 — intervention group
Group type: EXPERIMENTAL
Intervention: [(64)Cu]DOTA-patritumab
Number of subjects: 8
Study 26567120 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypotensive therapy
Number of subjects: 367
Study 26567120 — intervention group
Group type: COMPARATOR
Intervention: No antihypotensive therapy
Number of subjects: 367
Study 26567259 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroAiD (MLC601, MLC901)
Number of subjects: 2000
Study 26567860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 8
Study 26567860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose infusion (IVGI)
Number of subjects: 8
Study 26567860 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin effect calculation
Number of subjects: 8
Study 26567860 — intervention group
Group type: COMPARATOR
Intervention: Proinflammatory cytokines measurement
Number of subjects: 8
Study 26567860 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous response of GIP and glucagon
Number of subjects: 8
Study 26568466 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day treatment (15 mg/m² every 8 hours for three consecutive days/cycle/6 weeks)
Number of subjects: 135
Study 26568466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day treatment (20 mg/m² once daily on days 1-5/cycle/4 weeks)
Number of subjects: 135
Study 26568466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (3-day and 5-day)
Number of subjects: 135